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Abstract
Background: Escherichia coli sequence type 131 (ST131) is a successful clonal group that has dramatically spread
during the last decades and is considered an important driver for the rapid increase of quinolone resistance in E. coli.
Methods: Risk factors for rectal colonization by ST131 Escherichia coli (irrespective of ESBL production) were
investigated in 64 household members (18 were colonized) and 54 hospital contacts (HC; 10 colonized) of 34 and 30
index patients with community and nosocomial infection due to these organisms, respectively, using multilevel
analysis with a p limit of < 0.1.
Result: Colonization among household members was associated with the use of proton-pump inhibitors (PPI) by the
household member (OR = 3.08; 95% CI: 0.88–10.8) and higher age of index patients (OR = 1.05; 95% CI; 1.01–1.10), and
among HC, with being bed-ridden (OR = 21.1; 95% CI: 3.61–160.0) and having a urinary catheter (OR = 8.4; 95% CI: 0.87–76.9).
Conclusion: Use of PPI and variables associated with higher need of person-to-person contact are associated with increased
risk of rectal colonization by ST131. These results should be considered for infection control purposes.
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Introduction
Escherichia coli is among the most frequent cause of
bacterial infection in humans, particularly in the urinary
and digestive tracts. Therefore, antimicrobial resistance
in E. coli has important consequences for antibiotic use.
E. coli sequence type 131 (ST131) is a successful clonal
group that has dramatically spread during the last de-
cades, and is considered an important driver for the
rapid increase in antimicrobial resistance in E. coli to
quinolones; also some lineages of this clone, such us
H30Rx clade C2, have been linked to the dissemination
of the extended-spectrum β-lactamases (ESBL)
CTX-M-15 and CTX-M-14 [1–3]. Importantly, these
isolates usually exhibit the virulence factors associated
with extraintestinal pathogenic E. coli strains [1]. There-
fore, ST131 is important because of its combination of
successful spread, antibiotic resistance and virulence.
Most epidemiological studies on intestinal colonisation
by ST131 has been performed on isolates producing
ESBLs. However, most ST131 isolated from rectal [4] or
clinical samples [5] do not produce ESBLs. Thus, investi-
gating the epidemiology of ST131 is challenging because
these isolates lack a specific susceptibility marker, so that
molecular methods must be applied to a high number of
E. coli isolates in order to identify those belonging to
ST131 clonal group. This is complex for prospective
studies. Therefore, our knowledge about risk factors for
the acquisition of non-ESBL-producing ST131 is very
limited but would be relevant from an infection control
perspective. The objectives of this study were to investi-
gate the risk factor for colonization among contacts of
patients infected with ST131 E. coli irrespective of ESBL
production, in the community and hospitals.
Methods
The risk factors for colonisation with ST131 E. coli were
studied using a case-control design in 34 community
and 30 hospital clusters, conducted at Hospital Universi-
tario Virgen Macarena, a tertiary hospital attending
* Correspondence: imoralesjerez@hotmail.com
1Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital
Universitario Virgen Macarena, Seville, Spain
2Departamentos de Medicina y Microbiología, Universidad de Sevilla / CSIC/
Instituto de Biomedicina de Sevilla, Seville, Spain
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Morales Barroso et al. Antimicrobial Resistance and Infection Control           (2018) 7:135 
https://doi.org/10.1186/s13756-018-0427-9
550.000 population in Seville, Spain, from April 2012 to
April 2013. The study design was previously reported [6].
Briefly, the clusters were identified from an “index patient”
suffering an infection due to ST131 E. coli (detected by
PCR for O25b rfb4, allele 3 of the pabB gene and for the
B23 phylogroup), and was formed by his/her contacts.
Community index patients (n = 34) were attending the
emergency department and had not been admitted to the
hospital during the previous month, and nosocomial index
patients (n = 30) were hospitalized for > 48 h when the
sample was obtained. The household members of each
index community index patients (n = 64; median per index
patient, 2; range 1–4) formed the community clusters, and
the patients admitted to the same or nearest rooms and
attended by the same team of nurses as the nosocomial
index patient (n = 54; median, 2; range, 1–6) formed the
nosocomial clusters. Rectal colonisation by ST131 E. coli
was studied in all participants by performing rectal swabs
within one week of index case detection, and 1 and
3 months later.
The microbiological procedures were previously reported
[4]; in summary, rectal swabs were inoculated to Brilliance
UTI agar, MacConkey agar containing 4 mg/L cefotaxime
and a blood agar plate; all distinct E. coli morphotypes were
screened for O25b/pabB3/B23. ESBL production was stud-
ied in all third-generation cephalosporin-resistant isolates
by the double-disk synergy test. Antibiotic susceptibility
was studied by broth microdilution according to Clinical
and Laboratory Standards Institute (CLSI) recommenda-
tions [7].
As previously reported, 18/64 (28.1%) household mem-
bers from 13/34 (38.2%) community clusters and 8/54
(14.8%) contacts from 8/30 (26.6%) nosocomial clusters
were colonized by ST131 E. coli in at least one of the 3
rectal swabs performed [4] (Fig. 1). Data were collected by
personal interviews using a predesign questionnaire with
the variables showed in Tables 1 and 2, before any infor-
mation about colonization status was known. To consider
both the individual and cluster levels of exposure to risk
factors for colonisation with ST131 E. coli, the variance
among patients in the clusters were the risk factors for
colonisation with ST131 E. coli in any of the 3 rectal swabs
were investigated using a multilevel logistic regression
analysis if the variance among patients in the clusters was
significant (P value by Wald test ≤0.2); in that case, a
two-level logistic regression analysis (level 1 was formed
by the individual participants and level 2 by clusters) was
performed. If p value by Wald test was > 0.2, a conditional
logistic regression was performed for level 1. Variables
were kept in the models if their p values were < 0.1. Mlwin
3.0 (University of Bristol, UK) and SPSS 21.0 (IBM Corp,
Armonk, New York, USA) were used for the analyses.
The Institutional Review Board of the Hospital Universi-
tario Virgen Macarena approved the study.
Results
The distribution of participants according to colonization
status and clusters is shown in Fig. 1. The univariate com-
parison in exposure to potential risk factors between the
18 colonized and 46 non-colonized participants from
community clusters, and between community clusters
with and without colonized member (13 and 21, respect-
ively) are shown in Table 1. The variables with a p value <
0.2 for their association to colonization were higher age,
being dependant for basic activities, not sharing bathroom
with index case, recent antibiotic use and proton pump in-
hibitors (PPI) use in the individual level, and age of the
index patient in the cluster level. The p value for the vari-
ance at the cluster level was 0.20; therefore, a multilevel
analysis was performed; the variables associated with
ST131 colonisation were PPI use in the individual level
and age of the index patient in the cluster level (Table 1).
The univariate comparison in exposure to potential risk
factors between the 10 colonized and 44 non-colonized
participants from nosocomial clusters, and between noso-
comial clusters with and without a colonized member (8
Fig. 1 Distribution of participants
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and 22, respectively) are shown in Table 2. The variables
with a p value < 0.2 for their association to colonization in
the individual level were age, being dependant for basic
activities or bed-ridden and having a urinary catheter; no
variable showed was selected in the cluster level. The p
value for the variance at the cluster level was 0.95; there-
fore, multilevel analysis was not performed; the variables
associated with colonisation in the multivariate condi-
tional logistic regression were being dependent for activ-
ities and urinary catheter (Table 2).
The susceptibility of ST131 isolates is shown in Table 3.
Overall, 6 isolates (21.4%) were ESBL-producers.
Discussion
Despite the obvious limitation related to low numbers, we
were able to identify some risk factors for rectal colonisa-
tion by ST131 in community and nosocomial clusters of
patients with infection due to these organisms. PPI use
and higher age in the index patients are associated with
intestinal colonisation with ST131 among household
members of patients with previous community-acquired
infection due to this organism; this is interesting as PPI
use has been found also to be a risk factor for colonisation
with ESBL-producers [8] and other enteric pathogens.
This might be related to the fact that PPI eliminate the
Table 1 Characteristics of ST131 E. coli colonized and non-colonized household members of index community patients. Data are
expressed as number of exposed patients (percentage) except where specified
Features of contacts
(individual level)
ST 131 colonized household
members (n = 18)
Non-ST131 colonized household
members (n = 46)
P Adjusted OR
(multilevel)
p
Median age in years (IQR) 55 (47.25–74) 48 (37–58.5) 0.06
Male gender 6 (33.3) 17 (37.0) 0.78
Median Charlson index (IQR) 0 (0–0) 0 (0–0) 0.42
Diabetes mellitus 2 (11.1) 3 (6.5) 0.61
Cancer 0 3 (6.5) 0.55
Recurrent urinary tract infections 1 (5.6) 0 0.28
Dependent for basic activities 2 (11.1) 0 0.07
Bed-ridden 1 (5.6) 0 0.28
Recurrent urinary tract infections 1 (5.6) 0 0.22
Urinary catheter 0 0
Usual caregiver of index patient 11 (61.1) 21 (45.6) 0.26
Contact with farm animals 1 (5.6) 1 (2.2) 0.48
Shared bathroom with index patient 14 (77.8) 42 (91.3) 0.14
Travel abroad in the previous 3 months 0 1 (2.2) 1
Sexual partner of index patient 6 (33.3) 14 (30.4) 0.82
Mean meal outside home > 3 days/week 3 (16.7) 6 (13.0) 0.70
Cook regularly at home 9 (50) 22 (47.8) 0.87
Eat chicken products ≥1 per week 11 (61.1) 28 (60.9) 0.98
Eat turkey products ≥1 per week 5 (27.8) 17 (37.0) 0.48
Eat raw vegetables ≥1 per week 17 (94.4) 39 (84.8) 0.29
Recent antibiotic use 3 (16.7) 1 (2.2) 0.06
Proton pump inhibitor use 9 (50.0) 12 (26.1) 0.06 3.08 (0.88–10.8) 0.07
Features of index patient
(cluster level)
Clusters with one or more ST131
colonized household member (n = 13)
Clusters without any ST131 colonized
household member (n = 21)
P
Median age in years (IQR) 79 (69.75–83.75) 67.5 (51.5–81) 0.16 1.05 (1.01–1.10) 0.05
Male gender 8 (61.5) 8 (38) 0.43
Bed-ridden 0 0 0.81
Dependent for basic activities 2 (15.3) 2 (9.5) 0.65
Urinary catheter 4 (30.7) 3 (14.28) 0.36
Median Charlson index (IQR) 0.5 (0–2) 1.5 (0–2) 1
Pets at home 7 (53.8) 11 (52.4) 0.96
Recent antimicrobial use 9 (69.2) 13 (61.9) 0.84
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Table 2 Characteristics of ST131 E. coli colonized and non-colonized hospital contacts of index nosocomial patients. Data are
expressed as number of exposed patients (percentage) except where specified
Features of contacts
(individual level)
ST 131 colonized hospital
contacts (n = 10)
Non-ST131 colonized hospital
contacts (n = 44)
P Adjusted OR p
Median age in years (IQR) 81.5 (75.5–87.75) 6.08 (59.75–80.0) 0.05
Male gender 5 (50.0) 20 (45.4) 0.79
Median Charlson index (IQR) 1 (0.25–5) 1 (0–3.75) 0.76
Diabetes mellitus 3 (30.0) 15 (34.0) 0.80
Cancer 3 (30.0) 13 (29.5) 0.98
Liver cirrosis 0 1 (2.2) 1
Recurrent urinary tract infections 1 (10.0) 1 (2.2) 0.34
Dependent for basic activities 5 (50.0) 3 (6.8) 0.003 21.1 (3.61–160.0) 0.001
Bed-ridden 1 (10.0) 0 0.18
Shared room with index patient 7 (70.0) 24 (54.5) 0.37
Surgery during present admission 4 (40.0) 15 (34.0) 0.72
Urinary catheter 6 (60.0) 12 (27.2) 0.19 8.4 (0.97–76.9) 0.05
Recent antimicrobial use 4 (40.0) 16 (36.3) 0.83
Proton pump inhibitor use 6 (60.0) 34 (77.2) 0.85
Median (IQR) days of
hospital stay
5.5 (4.0–11.25) 6 (3.75–9) 0.70
Features of index patient
(cluster level)
Clusters with at least one ST131
colonized hospital contact (n = 8)
Clusters without any ST131 colonized
hospital contact (n = 22)
P
Median age in years (IQR) 62.50 (52.75–78) 67.10 (58.25–80.75) 0.70
Male gender 5 (62.5) 6 (27.3) 0.28
Median Charlson index (IQR) 2.60 (0–6) 2.40 (0–6) 0.7
Bed-ridden 0 3 (13.6) 0.53
Dependent for basic activities 2 (25) 4 (18.1) 0.73
Admission to a surgical ward 4 (50) 8 (36.3) 0.66
Admission to a medical ward 5 (62.5) 11 (50) 0.74
Admission to an intensive care unit 1 (12.5) 0 0.21
Surgery during present admission 4 (50) 5 (22.7) 0.39
Urinary catheter 7 (87.5) 10 (45.4) 0.76
Recent antimicrobial use 7 (87.5) 10 (45.4) 0.42
Median (IQR) days of hospital stay 27.2 (7–46) 35.5 (14.75–24) 0.59
Table 3 Antimicrobial susceptibility of ST131 Escherichia coli isolates. Data are number of susceptible isolates (percentage)
Antimicrobial All isolates (n = 28) Isolates from household members (n = 18) Isolates from hospital contacts (n = 10)
Ampicillin 6 (21.4) 6 (33.3) 0
Amoxicillin-clavulanic acid 9 (31.2) 9 (50) 0
Piperacillin-tazobactam 27 (96.4) 18 (100) 9 (90)
Ceftriaxone 22 (78.5) 15 (83.3) 7 (70)
Ceftazidime 22 (78.5) 15 (83.3) 7 (70)
Ertapenem 28 (100) 18 (100) 10 (100)
Ciprofloxacin 9 (32.1) 6 (33.3) 3 (30)
Gentamicin 24 (85.7) 17 (94.4) 7 (70)
Tobramycin 19 (67.8) 14 (77.8) 5 (50)
Amikacin 28 (100) 18 (100) 10 (100)
Fosfomycin 28 (100) 18 (100) 10 (100)
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barrier that the acid content of the stomach pose to di-
gestive tract colonisation of exogenous bacteria by inges-
tion. The higher age in index patients may be interpreted
as higher need for care and therefore more frequent con-
tact. In hospitals, the risk factors found (dependence for
basic activities and urinary catheter) might also be associ-
ated with increased need for care and contact. These re-
sults suggest that direct contact would be a prominent
mechanism of transmission for ST131 and build on the
concept that avoiding such direct person-to-person trans-
mission would be critical to reduce the spread of these
isolates [9].
The information about risk factors for colonisation
with ST131 is scant. While household transmission of
ST131 isolates has been well demonstrated [6, 10], we
could find no studies investigating the risk factors for
transmission. In healthcare centers, Han et al. could not
identify relevant differences between 29 and 8 long-term
care facility (LTCF) residents colonized with ST131 and
non-ST131 fluoroquinolone-resistant E. coli. [11]; in an-
other study in a LTCF, Burgess et al. found that time of
admission, being unable to sign consent, decubitus ulcer
and fecal incontinence were risk factors for colonisation
with ciprofloxacin-resistant ST131 E. coli [12]. Other
studies only investigated ESBL-producing ST131 isolates
[1, 2].
Previous antibiotic use was not identified as risk factor
in those studies or in the present one; however, we found
exposure to antibiotics (specifically amoxicillin-clavulanic
acid and fluoroquinolones) to be associated with increased
risk of infection due to ST131 [13]. While it may just be a
problem of statistical power, antibiotics might be more
important in the case of infections by selecting ST131 in
the gut of already colonized persons than as a factor
clearly favouring colonization.
This study has limitations that should be considered,
including a limited statistical power to detect risk factors
due to small sample size in relation with the difficulties
in performing a study on colonization with bacteria for
which no phenotypic marker exists; the sensitivity of de-
tection of ST131 from rectal swabs might be lower than
desired; and the results might be applicable only to clus-
ters with an infected person and areas with a similar epi-
demiology and clades of ST131.
Conclusion
In conclusion, use of PPI and variables associated with
higher need of person-to-person contact are associated with
increased risk of rectal colonization by ST131. These results
should be considered for infection control purposes.
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